O	0	1	A
O	2	12	Randomized
O	13	23	Controlled
O	24	29	Trial
O	30	32	of
B-intervention	33	38	Green
I-intervention	39	42	Tea
I-intervention	43	50	Extract
O	51	66	Supplementation
O	67	70	and
O	71	83	Mammographic
O	84	91	Density
O	92	94	in
O	95	109	Postmenopausal
O	110	115	Women
O	116	118	at
O	119	128	Increased
O	129	133	Risk
O	134	136	of
O	137	143	Breast
O	144	150	Cancer
O	150	151	.

O	152	165	Epidemiologic
O	166	169	and
O	170	176	animal
O	177	184	studies
O	185	192	suggest
O	193	194	a
O	195	205	protective
O	206	210	role
O	211	213	of
O	214	219	green
O	220	223	tea
O	224	231	against
O	232	238	breast
O	239	245	cancer
O	245	246	.

O	247	254	However
O	254	255	,
O	256	259	the
O	260	270	underlying
O	271	280	mechanism
O	281	283	is
O	284	287	not
O	288	298	understood
O	298	299	.

O	300	302	We
O	303	312	conducted
O	313	314	a
O	315	325	randomized
O	325	326	,
O	327	333	double
O	333	334	-
O	334	341	blinded
O	341	342	,
O	343	350	placebo
O	350	351	-
O	351	361	controlled
O	362	367	phase
O	368	370	II
O	371	379	clinical
O	380	385	trial
O	386	388	to
O	389	400	investigate
O	401	408	whether
O	409	424	supplementation
O	425	429	with
O	430	435	green
O	436	439	tea
O	440	447	extract
O	448	449	(
O	449	452	GTE
O	452	453	)
O	454	462	modifies
O	463	475	mammographic
O	476	483	density
O	484	485	(
O	485	487	MD
O	487	488	)
O	488	489	,
O	490	492	as
O	493	494	a
O	495	504	potential
O	505	514	mechanism
O	514	515	,
O	516	525	involving
B-total-participants	526	527	1
I-total-participants	527	528	,
I-total-participants	528	531	075
B-eligibility	532	539	healthy
I-eligibility	540	554	postmenopausal
I-eligibility	555	560	women
O	560	561	.

O	562	567	Women
O	568	576	assigned
O	577	579	to
O	580	583	the
O	584	593	treatment
O	594	597	arm
O	598	606	consumed
O	607	612	daily
O	613	614	4
O	615	628	decaffeinated
O	629	632	GTE
O	633	641	capsules
O	642	652	containing
O	653	654	1
O	654	655	,
O	655	658	315
O	659	661	mg
O	662	667	total
O	668	677	catechins
O	677	678	,
O	679	688	including
O	689	692	843
O	693	695	mg
O	696	712	epigallocatechin
O	712	713	-
O	713	714	3
O	714	715	-
O	715	722	gallate
O	723	724	(
O	724	728	EGCG
O	728	729	)
O	730	733	for
O	734	736	12
O	737	743	months
O	743	744	.

O	745	746	A
O	747	755	computer
O	755	756	-
O	756	764	assisted
O	765	771	method
O	772	773	(
O	773	779	Madena
O	779	780	)
O	781	784	was
O	785	789	used
O	790	792	to
O	793	799	assess
O	800	802	MD
O	803	805	in
O	806	813	digital
O	814	824	mammograms
O	825	827	at
O	828	836	baseline
O	837	840	and
O	841	846	month
O	847	849	12
O	850	854	time
O	855	861	points
O	862	864	in
B-total-participants	865	868	932
O	869	879	completers
O	880	881	(
B-intervention-participants	881	884	462
O	885	887	in
O	888	891	GTE
O	892	895	and
B-control-participants	896	899	470
O	900	902	in
B-control	903	910	placebo
O	910	911	)
O	911	912	.

O	913	916	GTE
O	917	932	supplementation
O	933	936	for
O	937	939	12
O	940	946	months
O	947	950	did
O	951	954	not
O	955	968	significantly
O	969	975	change
O	976	983	percent
O	984	986	MD
O	987	988	(
O	988	991	PMD
O	991	992	)
O	993	995	or
O	996	1004	absolute
O	1005	1007	MD
O	1008	1010	in
O	1011	1014	all
O	1015	1020	women
O	1020	1021	.

O	1022	1024	In
O	1025	1032	younger
O	1033	1038	women
O	1039	1040	(
O	1040	1042	50
O	1042	1043	-
O	1043	1045	55
O	1046	1051	years
O	1051	1052	)
O	1052	1053	,
O	1054	1057	GTE
O	1058	1073	supplementation
O	1074	1087	significantly
O	1088	1095	reduced
B-outcome	1096	1099	PMD
O	1100	1102	by
B-iv-bin-percent	1103	1104	4
I-iv-bin-percent	1104	1105	.
I-iv-bin-percent	1105	1107	40
I-iv-bin-percent	1107	1108	%
O	1109	1111	as
O	1112	1120	compared
O	1121	1125	with
O	1126	1129	the
O	1130	1137	placebo
O	1138	1142	with
O	1143	1144	a
B-cv-bin-percent	1145	1146	1
I-cv-bin-percent	1146	1147	.
I-cv-bin-percent	1147	1149	02
I-cv-bin-percent	1149	1150	%
O	1151	1154	PMD
O	1155	1163	increase
O	1164	1168	from
O	1169	1172	pre
O	1172	1173	-
O	1174	1176	to
O	1177	1193	postintervention
O	1194	1195	(
O	1195	1196	P
O	1197	1198	=
O	1199	1200	0
O	1200	1201	.
O	1201	1203	05
O	1203	1204	)
O	1204	1205	,
O	1206	1209	but
O	1210	1213	had
O	1214	1216	no
O	1217	1223	effect
O	1224	1226	in
O	1227	1232	older
O	1233	1238	women
O	1239	1240	(
O	1240	1252	Pinteraction
O	1253	1254	=
O	1255	1256	0
O	1256	1257	.
O	1257	1259	07
O	1259	1260	)
O	1260	1261	.

O	1262	1265	GTE
O	1266	1281	supplementation
O	1282	1285	did
O	1286	1289	not
O	1290	1296	induce
B-outcome	1297	1299	MD
I-outcome	1300	1306	change
O	1307	1309	in
O	1310	1315	other
O	1316	1325	subgroups
O	1326	1328	of
O	1329	1334	women
O	1335	1345	stratified
O	1346	1348	by
O	1349	1357	catechol
O	1357	1358	-
O	1358	1359	O
O	1359	1360	-
O	1360	1377	methyltransferase
O	1378	1386	genotype
O	1387	1389	or
O	1390	1395	level
O	1396	1398	of
O	1399	1403	body
O	1404	1408	mass
O	1409	1414	index
O	1414	1415	.

O	1416	1418	In
O	1419	1429	conclusion
O	1429	1430	,
O	1431	1432	1
O	1432	1433	-
O	1433	1437	year
O	1438	1453	supplementation
O	1454	1458	with
O	1459	1460	a
O	1461	1465	high
O	1466	1470	dose
O	1471	1473	of
O	1474	1478	EGCG
O	1479	1482	did
O	1483	1486	not
O	1487	1491	have
O	1492	1493	a
O	1494	1505	significant
O	1506	1512	effect
O	1513	1515	on
O	1516	1518	MD
O	1519	1527	measures
O	1528	1530	in
O	1531	1534	all
O	1535	1540	women
O	1540	1541	,
O	1542	1545	but
O	1546	1553	reduced
B-outcome	1554	1557	PMD
I-outcome	1558	1560	in
O	1561	1568	younger
O	1569	1574	women
O	1574	1575	,
O	1576	1578	an
O	1579	1582	age
O	1582	1583	-
O	1583	1592	dependent
O	1593	1599	effect
O	1600	1607	similar
O	1608	1610	to
O	1611	1616	those
O	1617	1619	of
O	1620	1629	tamoxifen
O	1629	1630	.

O	1631	1638	Further
O	1639	1652	investigation
O	1653	1655	of
O	1656	1659	the
O	1660	1669	potential
O	1670	1685	chemopreventive
O	1686	1692	effect
O	1693	1695	of
O	1696	1701	green
O	1702	1705	tea
O	1706	1712	intake
O	1713	1715	on
O	1716	1722	breast
O	1723	1729	cancer
O	1730	1734	risk
O	1735	1737	in
O	1738	1745	younger
O	1746	1751	women
O	1752	1754	is
O	1755	1764	warranted
O	1764	1765	.

O	1766	1772	Cancer
O	1773	1777	Prev
O	1778	1781	Res
O	1781	1782	;
O	1783	1785	10
O	1785	1786	(
O	1786	1788	12
O	1788	1789	)
O	1789	1790	;
O	1791	1794	710
O	1794	1795	-
O	1795	1796	8
O	1796	1797	.

O	1798	1799	Â©
O	1799	1803	2017
O	1804	1808	AACR
O	1808	1809	.
